Comparison of cancer risk estimates based on a variety of risk assessment methodologies
- PMID: 12662908
- DOI: 10.1016/s0273-2300(02)00026-0
Comparison of cancer risk estimates based on a variety of risk assessment methodologies
Abstract
The EPA guidelines recommend a benchmark dose as a point of departure (PoD) for low-dose cancer risk assessment. Generally the PoD is the lower 95% confidence limit on the dose estimated to produce an extra lifetime cancer risk of 10% (LTD(10)). Due to the relatively narrow range of doses in two-year bioassays and the limited range of statistically significant tumor incidence rates, the estimate of the LTD(10) is constrained to a relatively narrow range of values. Because of this constraint, simple, quick estimates of the LTD(10) can be readily obtained for hundreds of rodent carcinogens from the Carcinogenic Potency Database (CPDB) of Gold et al. Three estimation procedures for LTD(10) are described, using increasing information from the CPDB: (A) based on only the maximum tolerated dose (the highest dose tested); (B) based on the TD(50); and (C) based on the TD(50) and its lower 99% confidence limit. As expected, results indicate overall similarity of the LTD(10) estimates and the value of using additional information. For Method (C) the estimator based on the [[(TD(50))(0.36) x (LoConf)(0.64)]/6.6] is generally similar to the estimator based on the one-hit model or multistage model LTD(10). This simple estimate of the LTD(10) is applicable for both linear and curved dose responses with high or low background tumor rates, and whether the confidence limits on the TD(50) are wide or tight. The EPA guidelines provide for a margin of exposure approach if data are sufficient to support a nonlinear dose-response. The reference dose for cancer for a nonlinear dose-response curve based on a 10,000-fold uncertainty (safety) factor from the LTD(10), i.e., the LTD(10)/10,000, is mathematically equivalent to the value for a linear extrapolation from the LTD(10) to the dose corresponding to a cancer risk of <10(-5) (LTD(10)/10,000). The cancer risk at <10(-5) obtained by using the q(1)(*) from the multistage model, is similar to LTD(10)/10,000. For a nonlinear case, an uncertainty factor of less than 10,000 is likely to be used, which would result in a higher (less stringent) acceptable exposure level.
Copyright 2003 Elsevier Science (USA)
Similar articles
-
Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.Regul Toxicol Pharmacol. 1998 Dec;28(3):222-5. doi: 10.1006/rtph.1998.1258. Regul Toxicol Pharmacol. 1998. PMID: 10049793
-
Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?Regul Toxicol Pharmacol. 2005 Mar;41(2):128-33. doi: 10.1016/j.yrtph.2004.11.001. Epub 2004 Dec 19. Regul Toxicol Pharmacol. 2005. PMID: 15698536
-
Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat.Risk Anal. 2000 Feb;20(1):135-51. doi: 10.1111/0272-4332.00013. Risk Anal. 2000. PMID: 10795346
-
The linearized multistage model and the future of quantitative risk assessment.Hum Exp Toxicol. 1996 Oct;15(10):787-98. doi: 10.1177/096032719601501001. Hum Exp Toxicol. 1996. PMID: 8906427 Review.
-
Chloroform mode of action: implications for cancer risk assessment.Regul Toxicol Pharmacol. 1997 Oct;26(2):142-55. doi: 10.1006/rtph.1997.1161. Regul Toxicol Pharmacol. 1997. PMID: 9356278 Review.
Cited by
-
Risk Assessment of Chlorogenic and Isochlorogenic Acids in Coffee By-Products.Molecules. 2023 Jul 20;28(14):5540. doi: 10.3390/molecules28145540. Molecules. 2023. PMID: 37513412 Free PMC article. Review.
-
Risk Assessment of Trigonelline in Coffee and Coffee By-Products.Molecules. 2023 Apr 14;28(8):3460. doi: 10.3390/molecules28083460. Molecules. 2023. PMID: 37110693 Free PMC article. Review.
-
Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.Sci Rep. 2015 Jan 30;5:8126. doi: 10.1038/srep08126. Sci Rep. 2015. PMID: 25634572 Free PMC article.
-
The impact of population heterogeneity on risk estimation in genetic counseling.BMC Med Genet. 2004 Jun 30;5:18. doi: 10.1186/1471-2350-5-18. BMC Med Genet. 2004. PMID: 15228628 Free PMC article.
-
Generic Hockey-Stick Model for Estimating Benchmark Dose and Potency: Performance Relative to BMDS and Application to Anthraquinone.Dose Response. 2011;9(2):182-208. doi: 10.2203/dose-response.10-018.Bogen. Epub 2010 Oct 21. Dose Response. 2011. PMID: 21731536 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials